Free Trial
TSE:FRX

Fennec Pharmaceuticals 11/6/2023 Earnings Report

Fennec Pharmaceuticals logo
C$11.15 +0.14 (+1.27%)
As of 08/6/2025 11:01 AM Eastern

Fennec Pharmaceuticals EPS Results

Actual EPS
-C$0.09
Consensus EPS
-C$0.15
Beat/Miss
Beat by +C$0.06
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
$8.74 million
Expected Revenue
$6.94 million
Beat/Miss
Beat by +$1.80 million
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Fennec Pharmaceuticals Earnings Headlines

Fennec Pharmaceuticals Inc. (FENC) - Yahoo Finance
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Fennec reports Q4 EPS (6c), consensus (13c)
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (TSE:FRX) Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat